Pancreatic neuroendocrine neoplasms (PNEN) present a complex diagnostic and therapeutic landscape, demanding nuanced approaches for optimal patient care. Diagnosis relies on a blend of imaging modalities such as CT (computed tomography), MRI (magnetic resonance imaging), and somatostatin receptor imaging, aiding in lesion localization and characterization. Functional assessment, crucial in PNEN due to varied hormone production, necessitates meticulous hormonal assays. Histopathological grading, from well differentiated to poorly differentiated tumors, influences treatment decisions. The TNM staging system, integrating tumor size, nodal involvement, and metastasis, guides prognostication and management strategies. Therapeutically, surgery remains a cornerstone, especially for localized disease. Peptide receptor radionuclide therapy (PRRT) and molecular targeted therapies highlight promising avenues for metastatic cases, emphasizing personalized treatment paradigms. Navigating through multidisciplinary collaborations, integrating evolving imaging technologies, refining grading and staging criteria, and embracing targeted therapies underscore a progressive trajectory in managing PNEN, enhancing survival outcomes, and refining quality of life for affected individuals.